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The Korea Advisory Committee on Immunization Practices (KACIP), established by law in the early 1990s,ecision-making
dvisory committee
outh Korea
makes recommendations on a range of issues related to the National Immunization Program. The Com-
mittee consists of 15 members and always includes the two government ofﬁcials who belong to the
Korea Centers for Disease Control and Prevention and the Korea Food and Drug Administration. Other
members usually come from afﬁliated organizations and serve for 2-year terms. The KACIP depends on
special-topics sub-committees or temporary advisory committees to gather andanalyzedata and tomake
recommendations which are normally reached by consensus and implemented by public sector health
vider
. providers and private pro
. Introduction
Immunization is among the most effective public health mea-
ures to prevent disease. Recommendations concerning the use of
ew vaccines, based on evidence – such as vaccine safety, efﬁcacy
nd cost-effectiveness, and the public’s acceptance of the vaccine
are thus critical to improve a country’s public health. The Korea
dvisory Committee on Immunization Practices (KACIP) is an advi-
ory organ of theMinistry ofHealth (MoH) that provides advice and
uidance on the control of vaccine-preventable diseases (VPD). In
ecent years, a number of new vaccines have been introduced into
he National Immunization Program (NIP) (Tables 1 and 2), with
he KACIP playing an increasingly larger and more visible role in
he decision-making process. This article describes the history and
tructure of the KACIP,meeting procedures, the process of develop-
ng recommendations, and limitations in how the KACIP functions.. History of the KACIP
The MoH ordered the establishment of the KACIP in June 1992
o advise the MoH on the control of VPD and immunization-related
Abbreviations: Epi, Expanded Program of Immunization; KACIP, Korea Advisory
ommittee on Immunization Practices; KCDC, Korea Centers for Disease Control and
revention; KFDA, Korea Food and Drug Administration; MoH, Ministry of Health;
IP, National Immunization Program; WHO, World Health Organization; WPRO,
estern Paciﬁc Regional Ofﬁce.
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policy. The goal of establishing the KACIP was to both prevent and
control VPD and ensure the safety of vaccination. The main respon-
sibilities of the KACIP are to: (1) designate diseases to be targeted
for immunization and remove diseases from the list, as needed; (2)
develop plans for the control of communicable diseases; and (3)
develop practical guidelines and policies for immunization. These
responsibilities of the Committee cover both the private sector –
which provides around 60% of immunizations in the country – and
the public sector. However, only public facilities are mandated by
law to follow all KACIP recommendations approved by the MoH.
In August 1994, the KACIP became a legal entity under the Preven-
tion of Contagious Diseases Act [1]. This was prompted by reports
of adverse events associated with Japanese Encephalitis vaccina-
tion, subsequently shown to be due to poor storage of the vaccine.
With its legal designation camedetailed rules concerning the struc-
ture, terms of reference and functioning of the Committee. The ﬁrst
Committee established under these rules began in February 1995
and discussed a number of key topics, including the development
of guidelines for the NIP, the issue of compensation for vaccine-
related injuries, introduction ofHaemophilus inﬂuenzae type b (Hib)
vaccine, guidelines for vaccination against Korean hemorrhagic
fever, and a review of a sero-epidemiologic survey of diphtheria
in adults. The Committee also established a sub-committee for the
investigation of vaccine-related injuries,whichwas separated from
the KACIP and became the Advisory Committee on Vaccine Injury
Open access under CC BY-NC-ND licenseCompensation in 2003.
Committee members are appointed to 2-year terms that all
begin at the same time, and thus anewcommittee is formedevery 2
years. However certain ofﬁcials, who serve as a result of their posi-
tion within the government will remain on the Committee for as
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Table 1
The history of vaccination in the Republic of Korea.
Year Key milestones or activities
1912 Vaccines for cholera and smallpox was introduced
1948 Bacillus Calmette–Guérin (BCG) vaccine was introduced
1954 Expanded Program of Immunization was established by government decree (to cover 8 diseases, including typhoid, diphtheria, pertussis,
tetanus, tuberculosis, cholera, and smallpox)
1955 Diphtheria/pertussis/tetanus (DPT) vaccine was introduced
1965 Measles vaccine was introduced
1973 Japanese Encephalitis vaccine introduced
1980 Measles–mumps–rubella (MMR) vaccine was introduced
1995 Hepatitis B vaccine was included in National Immunization Program
1997 2nd MMR dose was added to the routine immunization schedule
2001 Measles catch up campaigns were initiated in response to epidemics
2004 Tetanus/diphtheria (Td) vaccine was introduced
Oral polio vaccine was replaced by inactivated polio vaccine
2005 Varicella vaccine was added to the infant vaccine schedule
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the years, Committee members have made recommendations to
include more female members, representatives from civil society,
and people from rural areas, though to date there are no minimum
requirements or quotas for representation of these groups.2006 Achievement of measles elimination was declared
2007 Certiﬁcation of the achievement of control of vertic
2009 The Korea Centers for Disease Control and Preventi
and facilities
ong as they remain in their position (see next section). Despite this
ntention, the duration of the current – seventh – committee,which
as formed in October 2007, has been extended to a third year,
ecause of themany issues it has beendealingwith that still need to
e resolved. This is theﬁrst time that theCommittee’s termhasbeen
xtended and the terms will go back to 2 years in 2010. Among the
tems on the agenda of the current committee have been: a review
f national immunization strategies; the control ofmeasles; how to
ontrol a hepatitis A outbreak; the control of varicella and mumps;
hether to change the strain of Bacillus Calmette–Guérin (BCG)
accine and route of administration (from intradermal to transder-
al); and the issue of subsidizing the cost of Expanded Program of
mmunization (EPI) vaccines provided through the private sector,
hrough which the majority of immunizations in Korea are given.
ased on a recommendation by the KACIP, the Government has
ecided to partially subsidize the cost of all EPI vaccines admin-
stered at private health facilities that agree to participate in this
rogram, starting in 2009 (with parents now paying 70% instead of
00% of the vaccine cost).
. Composition of the KACIP
The KACIP consists of a Chairperson and specialists in inter-
al medicine, paediatrics, obstetrics, microbiology, preventive
edicine and nursing. The Committee also includes a representa-
ive from a consumer group, the Director of Disease Prevention at
he Korea Centers for Disease Control and Prevention (KCDC), and
heDirector of Biologics at the Korea Food andDrugAdministration
KFDA). Apart from the two government ofﬁcials mentioned above,
ll other members usually come from the afﬁliated organizations
able 2
accines included in the National Immunization Program in the Republic of Korea,
009.
Bacillus Calmette–Guérin BCG (intradermal)
Hepatitis B
Diphtheria/tetanus/pertussis (DTP)
Inactivated poliovirus vaccine (IPV)
Measles/mumps/rubella (MMR)
Varicella
Japanese Encephalitis vaccine (inactivated)
Tetanus/Diphtheria (Td, adult)
Inﬂuenza
Typhoid fever (oral Ty21a and Vi polysaccharide) for food handlers and
travellers to developing countries
Korean hemorrhagic feversmission of hepatitis B was granted by World Health Organization
ins program to provide free vaccines to participating private sector providers
shown in Fig. 1, which each nominate one member. The total num-
ber of Committee members is usually around 15. The Secretariat
of the Committee is within the KCDC, which funds, organizes and
prepares for the meetings, and at whose headquarters the meet-
ings are held. The Chairperson rotates every term (i.e., 2 years)
and can be selected from any ﬁeld or afﬁliated organization. OverFig. 1. Afﬁliated organizations of the KACIP.
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KACIP members are appointed by the MoH and, with the excep-
ion of the Director of Disease Prevention at the KCDC and the
FDA’s Director of Biologics, they serve for a term of 2 years. Mem-
ers can serve more than one term, and although there are no
ormal rules dictating the length of time members can serve on the
ommittee, historically members serve no more than two terms
i.e., 4 years). Representatives of the afﬁliated organizations nomi-
ate candidates and forward their names to the KCDC Director for
eview. The list of nominees is then sent to the Health Minister,
ho makes the ﬁnal selection. All members are given an ofﬁcial
ppointment letter.
When aperson joins theKACIP, he or shemust sign a declaration
f conﬁdentiality. Members have an obligation to notify the Com-
ittee if they have any business with a vaccine producer (e.g., as a
onsultant) and, if so, they must resign from the Committee. They
ust also report to the KCDC if they own any stock in vaccine com-
anies, recluse themselves fromvoting on an issuewithwhich they
re personally involved or if they are stockholders in a vaccine com-
any, and avoid interviews with the press if relevant ofﬁcials are
ot present.Members are given an allowance for travel expenses to
ttend the meetings. Members have an obligation to attend every
eeting – baring emergencies – and may be dismissed if they miss
wo meetings in a row without giving a reason.
In addition to these members, external experts, such as princi-
al investigators of vaccine clinical trials, KFDA ofﬁcials involved in
accine licensure, and more rarely, scientists from vaccine compa-
ies, may be asked to participate in certain meetings as ex-ofﬁcio
embers to lend their expertise on a particular topic. These experts
annot, however, participate in decision-making.
. Rules governing KACIP meetings and areas that the
ommittee addresses
According to the written rules governing the KACIP in the Pre-
ention of Contagious Diseases Act, the Committee must meet at
east four times a year, and additional meetings can be held, as
eeded, upon the request of the Minister of Health or more than
alf of the Committee members, with approval by the Chairperson.
n 2009, for example, a total of eight meetings were held, many to
iscuss planning for the introduction of a vaccine against the new
1N1 strain of inﬂuenza.
The Director of the Division of VPD Control and the NIP sets
p the agenda for each meeting, based on suggestions from KACIP
embers, KCDC staff, other experts and ex-ofﬁcio members, and
embersofKACIP sub-committees (describedbelow). Thedecision
o add a topic, such as the introduction of a new vaccine, to the
ACIP agenda can be prompted by the licensure of a new vaccine
y the KFDA for use in the private sector, the declaration of a new
oal by the World Health Organization (see Section 7), an outbreak
r increase in incidence of aVPD, orwhen speciﬁc issues related to a
accinearise (suchas reportsof adverseevents). Industrypersonnel
annot directly propose agenda topics for KACIP meetings, but can
uggest them through others, such as KFDA or KCDC staff or clinical
rial researchers.
The scopeofworkof theCommittee includes the following areas
nd issues:
disease control measures for VPD, including enhanced surveil-
lance, improved case management, and immunization;
the introduction and use of newvaccines, including ones recently
licensed by the KFDA;
recommendations concerning vaccine schedules, including tar-
get ages, number of doses and interval between doses;
vaccines for high-risk groups and for adults;
vaccine formulations;8S (2010) A91–A95 A93
• which vaccine to recommend when there are more than one
against a given disease; and
• recommendations for additional studies to aid decision-making,
such as sero-epidemiological surveys for a VPD or vaccine cost-
effectiveness analyses;
Other agenda items in recent meetings have included: a review
of data on the H1N1 inﬂuenza outbreak in Korea and what target
groups to prioritize for ﬂu vaccination; a review of vaccine adverse
events; changes in vaccine supply; and setting priorities for the
Korean NIP among new vaccines such as those against hepatitis
A, Hib, pneumococcal pneumonia, rotavirus, and human papilloma
virus (HPV).
As written in the Contagious Diseases Act, KACIP meetings are,
in principle, open to the public, and people wishing to attend a
meeting as observers, such as vaccine producers, members of civil
organizations or academia, must complete a written application at
least 5 days before themeeting. However, the Chairperson can hold
a meeting behind closed doors, if particularly sensitive or contro-
versial topics are being discussed. This was the case for a meeting
held in 2009 to decide which groups to target for H1N1 inﬂuenza
vaccination.
5. Sub-committees and special working groups
In 2003, the KACIP established a number of sub-committees
that function as working groups to gather, analyze, present
information and make recommendations on speciﬁc topics to
inform the Committee’s decision-making. There are now 12 sub-
committees, eachwith a speciﬁc area of expertise or focus (Table 3).
New sub-committees can be created or existing ones disbanded,
upon recommendation by the KACIP; however, all current sub-
committees have been in existence since 2003. They are usually
made up of less than 20 members, including some KACIP mem-
bers, representatives of the afﬁliated organizations and from
academia, as well as other external experts. As with the KACIP,
representatives from vaccine companies cannot serve on sub-
committees. The Director of the KCDC appoints the chairs of the
sub-committees, who are sometimes members of the KACIP. Sub-
committee members are recommended by the KCDC Director,
the Chair of the sub-committee and KACIP members, and are
approved by the KCDC Director. As with KACIP members, terms
for sub-committee members are 2 years. There are no rules gov-
erning the frequency of meetings of the various sub-committees;
rather they meet as necessary, such as when a topic related to
their areas of focus is on the agenda of upcoming KACIP meet-
ings.
In addition to these 12 long-term sub-committees, speciﬁc
working groups or advisory committees are sometimes established
on a temporary basis by the KCDC in response to new situa-
tions, such as the emergence of a new disease or the declaration
of global disease elimination goals by World Health Organiza-
tion (WHO). These working groups function very much the same
as the longer-term sub-committee, reporting their ﬁndings and
recommendations to the KACIP. Two such working groups are
the Advisory Committee for the Maintenance of Measles Elimi-
nation Status and the Advisory Committee on the Prevention of
Hepatitis B Vertical Transmission. A new working group estab-
lished in 2009 is the Advisory Committee on H1N1 inﬂuenza virus,
which is tasked with gathering data and making recommendations
regarding immunization against this new pandemic ﬂu strain. This
committee, made up of experts in paediatrics, internal medicine,
immunology, infectious disease, and preventive medicine, has
developed a set of recommendations for consideration by the
KACIP, addressing priority groups to target for vaccination, includ-
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Table 3
The sub-committees of the Korea Advisory Committee on Immunization Practices.
Sub-committee Main areas addressed
Tuberculosis Route of administration, selection of vaccine strain
Hepatitis A/hepatitis B vaccines Control of hepatitis A, including setting guidelines for immunization; seroprevalence of hepatitis B to determine
vaccine’s efﬁcacy
DTaP/polio vaccines Strategies for Td immunization for adolescents and adults; polio eradication strategies
Measles–mumps–rubella vaccines Strategies for the elimination of measles and rubella and control of mumps
Japanese Encephalitis vaccines Review of sero-epidemiological surveys of Japanese Encephalitis; consideration of use of live vaccine (SA 14-14-2) as
an alternative to the mouse-brain derived/killed vaccine
Inﬂuenza vaccines and adult
immunization
Identiﬁcation of priority target groups for seasonal inﬂuenza vaccination; development of strategies and guidelines
for adult immunization against inﬂuenza
Immunization registry Development and assessment of the web-based immunization registry program; development of immunization
reference manual for health workers
Vaccine adverse events Review of data from surveys of vaccine adverse events
Varicella vaccines Review of the efﬁcacy of and develop strategies for varicella immunization
Haemophilus inﬂuenza type
b/pneumococcus vaccines
Monitoring of disease burden in Korea and of disease burden and vaccination policy in other countries. Also examined
data on rotavirus for National Immunization Program prioritization for one meeting
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. Evidence and factors inﬂuencing decision-making
When a decision has been made to add a topic to the agenda
or the KACIP to address, the KCDC requests the appropriate sub-
ommittee or advisory committee to review all relevant data,
ather the opinions of experts, and suggest policy recommenda-
ions. If no sub-committeeor advisory committeeyet exists that can
ddress the topic, the KACIP requests the KCDC to gather relevant
ata for their review.
In considering the introduction of a newvaccine or other change
n the NIP, the relevant sub-committee and the KACIP examine all
vailable data – both published and unpublished – on the disease
urden in Korea, including clinical characteristics of the disease,
nd incidence, mortality, and case fatality rates. If local disease
urden data are lacking, the sub-committee will examine available
ata from other countries, such as Japan, or will recommend that a
ocal study be conducted.
The sub-committee also compiles and analyzes data on the
fﬁcacy, effectiveness, and safety of the vaccine, including side
ffects andcontraindications. Sourcesof informationon thevaccine
nclude clinical trials conducted both in Korea and in other coun-
ries,WHOpositionpapers, recommendationspublishedby theU.S.
enters for Disease Control and Prevention (www.cdc.gov), and
he European Centre for Disease Prevention and Control website
www.ecdc.europa.eu). Information on the availability of a vaccine
upply and sources of the vaccine are also considered. External
xperts are often asked to provide information and their views con-
erning thevaccineat both the sub-committee andKACIPmeetings.
or instance, the ofﬁcer from the KFDA who was responsible for
icensure of the vaccine in Korea may be asked to provide infor-
ation on the vaccine’s immunogenicity in the local population,
afety proﬁle, and clinical trial results.
WHOrecommendations are another key factor inﬂuencingdeci-
ions, including the goals and policies of the Western Paciﬁc
egional Ofﬁce (WPRO). The regional goals to eliminate measles
nd prevent the transmission of hepatitis B from mother to infant
ere instrumental in the establishment of the special advisoryadverse events following immunization; examination of disease burden in Korea
tional Immunization Program and analysis of the cost-effectiveness of
groups foreach topicand theenactmentofnationalpolicies to reach
both goals (see Section 7).
At the same time, the KCDC often compiles and reviews
economic data on the disease and vaccine, including the cost,
affordability and ﬁnancial sustainability of implementing the new
vaccine program, as well as the vaccine’s cost-effectiveness (in
terms of cost/QALY). This information, presented to the KACIP, is
often gathered and analyzedwith assistance froma local economist
or expert in preventive medicine. While global economic data from
WHO or from other countries are often used as a reference, data
from Korea are always preferred, and local studies are sometimes
recommended, since the economic and disease burden parameters
change from country to country. The results of economic evalua-
tions conducted by vaccine producers usually are not considered,
because of the obvious concern of bias.
The KACIP and sub-committees do not have set rules on ranking
thevarious factors and typesof data (e.g., diseaseburdenvs. vaccine
cost-effectiveness) in order of importance when making recom-
mendations. This is because speciﬁc factors, such as the potential
for disease outbreaks, whether the disease has seasonal peaks, and
the groups most affected by the disease (e.g., children vs. adults),
differ for each disease and thus the committee considers the pre-
ponderance of data when making recommendations.
Sub-committees also make recommendations concerning mea-
sures for controlling the disease they focus on that go beyond
immunization. For example, in response to an outbreak of
pertussis among infants, in 2009, the Sub-committee on Diph-
theria/Tetanus/Pertussis and Polio held meetings to develop
recommendations concerning case management and surveillance,
as well as immunization. These recommendations included the
isolation of pertussis patients and the distribution of antibiotics
for prophylactic use among the patient’s contacts; polymerase
chain reaction testing to diagnose all suspected pertussis patients,
where available; a survey to determine what proportion of
patients with chronic cough have pertussis; and the replacement
of the tetanus–diphtheria (Td) booster for adolescents with the
new tetanus–diphtheria–acellular pertussis (Tdap) vaccine. The
KCDC ordered the implementation of the medical-related rec-
ommendations immediately in public health facilities, while the
vaccine-related recommendations have been sent to the KACIP to
address at its next meeting in 2010.
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. Case study on KACIP’s role in reducing perinatal
ransmission of hepatitis B
The launch and successful implementation of Korea’s Hepati-
is B Perinatal Transmission Prevention Program illustrates the
mportant role of both the World Health Organization in setting
oals for the National Immunization Program, and the KACIP and
ncillary working groups in developing practical recommenda-
ions to achieve these goals. In 2002, the Western Paciﬁc Ofﬁce
f WHO (WPRO) set the goal for the region to reduce hepatitis B
ransmission from mothers to their infants, with a benchmark for
ountries to achieve a seroprevalence rate of hepatitis B surface
ntigen (HBsAg) in children 5 years and older of <2% by 2012 [2]. In
esponse, the KACIP established the following goals: (1) reduce the
eroprevalence rate of HbsAg in the total population to <1% within
0years; (2) achieve95%coverageof the3rddoseof hepatitis B vac-
ine in infants; and (3) strengthen the disease surveillance system
o monitor and evaluate progress with hepatitis B control.
The KCDC then established the Advisory Committee on the Pre-
ention of Hepatitis B Vertical Transmission, which recommended
series of strategies to meet the KACIP’s goals. These strategies
ncluded:
1) screening all pregnant women for chronic hepatitis B infection;
2) providing prophylactic treatment (hepatitis B immunoglobu-
lin) to all infants born to HBsAg positive mothers;
3) vaccinating all infants against hepatitis B.
o ensure compliance among providers and patients in the private
ector, the government implemented a voucher program. Through
his program, private clinics were given free vouchers, which were
hen distributed to pregnant women, who could use them to in
ieu of payment to cover the costs of vaccination of their infant, a
creening test to detect the hepatitis B surface antigen and surface
ntibody following the third dose of the vaccine, and revaccination
or infantswho fail to showan immune response to the vaccine. The
rivate clinics then submit the vouchers to the city or state govern-
ent to receive reimbursement for these services. The vouchers
lso serve as a data tracking device, as patient information on the
oucher is sent to the Korea CDC hepatitis B database. As a result
f this program, the prevalence of HBsAg among blood donors has
een reduced to 0–0.4% and coverage among infants for the third
epatitis B dose is 94%.WHO certiﬁed Korea as having achieved the
ontrol of vertical transmission of hepatitis B in 2008.
. The decision-making process
Once the sub-committee compiles and reviews the epidemi-
logical, vaccine, and economic data and hears from KCDC and
xternal experts, members try to reach a consensus on recommen-
ations concerning control measures for the disease in question,
ncluding immunization; target groups for vaccination; route of
dministration; andother key considerations. If the sub-committee
annot reach a consensus, it is the prerogative of the Chairperson
o decide what recommendations to give to the KACIP. A senior
fﬁcer from the KCDC summarizes the data, opinions and rec-
mmendations coming from the sub-committee and includes this
nformation in a bound document prepared for KACIP members for
ach meeting. This document also includes information and views
rom KCDC and other (non-industry) experts, as well as the meet-
[8S (2010) A91–A95 A95
ing agenda, recommendations from the previous meeting, and the
terms of reference of the Committee.
During the meetings of the KACIP, experts, including ex-ofﬁcio
members, ofﬁcials from the KFDA or the KCDC or members of
the relevant sub-committee, give presentations or are asked to
express their views. Members then discuss each issue in depth and
develop recommendations, usually by consensus. An ofﬁcer of the
KCDC records the recommendations or other results of the meet-
ing, which the KACIP Chairperson submits to the Director of the
KCDC, who in turn transmits the recommendations to the MoH.
The minutes of the KACIP meetings are given to the KCDC Director
and other staff, but are not made public.
While most decisions made by the Committee are approved by
the MoH and thus implemented, KACIP recommendations are not
legally binding, and there have been times where recommenda-
tions were not implemented for some time due to a lack of funding
or the need to revise laws in order to enact the policy change. For
example, theprogramrecommendedby theKACIP to subsidizepart
of the costs of EPI vaccines administered at private health facili-
ties (described above) required that the Prevention of Contagious
Diseases Act be revised, before it could be implemented.
9. Dissemination and implementation of KACIP
recommendations
If a recommendation is approved by the MoH, ofﬁcials of the
KCDC then develop a budget to cover the costs of the new policy
change (e.g., the introduction of a new vaccine), and plan the steps
necessary to implement the recommendation, working with both
public and private health facilities and organizations. The Public
Relations Department of the KCDC then prepares public educa-
tion materials, such as brochures, posters, and vaccine information
statements or factsheets to alert the public and medical commu-
nity of the new recommendations. In the case of a recommendation
involving the introduction of a new vaccine or changes in vacci-
nation guidelines, the KCDC, which publishes a national reference
manual on the epidemiology and prevention of VPD [3], in coopera-
tionwith theKACIP and theKoreanMedical Association, revises the
manual to include the new recommendations. Updated guidelines
incorporating the recommendations are also posted on the KCDC’s
website (www.cdc.go.kr).
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